Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Smith & Nephew plc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $27.7, while Smith & Nephew plc trades at $30.73 (market cap $12.81B). The key difference: Smith & Nephew plc pays a 2.54% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| FNGU | SNN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $38.70 |
52-Week Low | $13.73 | $28.73 |
Market Cap | — | $12.81B |
Enterprise Value | — | $15.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a leveraged ETN tracking the FANG+ Index, trades at $28.79, down 0.38% on the day. Technical indicators show mixed signals with moving averages bullish but oscillators bearish, including overbought RSI readings above 80. Recent performance highlights extreme volatility, with a documented 16% single-session drop on June 5, 2026, illustrating the amplified risks of its 3x leverage structure.
The outlook for FNGU is highly speculative, driven entirely by momentum in its underlying tech stocks rather than traditional fundamentals. Investment opportunity exists for aggressive traders betting on continued tech sector strength, but risks are severe, including decay from daily resets and catastrophic losses during market downturns, as recent news demonstrates.
Smith & Nephew (SNN) trades at $31.41, up 5.28% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $5.8B in 2024 to $6.2B projected for 2025 and net income margin expanding to 10.14%. Recent product launches in robotics and wound care, plus a $500M share buyback, highlight strategic execution. Analyst consensus is mixed with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility where two of the last four quarters missed expectations.
Outlook: SNN's recovery trajectory and product innovation support long-term growth, but investor patience is needed due to earnings inconsistency and moderate debt levels. Key risks include competitive pressures in medtech and execution on guidance. The stock presents a value opportunity if operational improvements continue, trading at reasonable valuations (P/E 21.5, P/S 2.18) versus sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
